Trials / Completed
CompletedNCT04295005
A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists
The Empagliflozin vs. DPP-4 Inhibitors and GLP-1 Receptor Agonists Cost of Care Study: a German Claims Data Analysis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 24,500 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Empagliflozin vs. Dipeptidyl Peptidase 4 (DPP-4) Inhibitors and Glucagon-like Peptide-1 Receptor Agonists (GLP-1-RA) Cost of Care Study: a German claims data analysis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Empagliflozin | film coated tablet |
| DRUG | DPP-4i | film coated tablets, specifically Sitagliptin |
| DRUG | GLP-1-RA | subcutaneous injection or tablet |
Timeline
- Start date
- 2020-11-16
- Primary completion
- 2021-09-30
- Completion
- 2021-09-30
- First posted
- 2020-03-04
- Last updated
- 2024-08-30
- Results posted
- 2024-08-30
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT04295005. Inclusion in this directory is not an endorsement.